Today: 7 February 2026
Subscribe

Marcin Frąckiewicz

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

NV Energy Stock Holds Steady Amid Nevada Utility Turmoil

NV Energy Stock Holds Steady Amid Nevada Utility Turmoil

Stock Performance & Trading NV Energy’s stock is essentially flat this week, closing at $23.74 per share on Oct. 24, 2025investing.cominvesting.com. The share price is right at its recent range (previous close $23.74, open $23.71, day’s high $23.75investing.com) and no new 52-week high or low is indicatedinvesting.com. In fact, the investing.com data shows zero price change (0.00%) on the latest quoteinvesting.com. Trading volume is negligible (no fresh trades were reported on Oct. 24), and the 3-month average volume is only about 1.76 million shares per dayinvesting.com. MarketBeat explicitly warns that NVE has been “marked as potentially delisted” and may not
24 October 2025
Grindr Stock Skyrockets on Buyout Buzz – What Investors Need to Know

Grindr Stock Skyrockets on Buyout Buzz – What Investors Need to Know

Buyout Buzz Sends GRND Soaring Grindr’s stock price skyrocketed after news of a potential insider buyout broke. On Friday, Oct. 24, GRND opened at $14.50 and surged as high as $16.22 intraday, an approximately 25% jump from the prior day’s closeinvesting.com. The rally came after Grindr confirmed that its two largest shareholders – board Chair James Fu Bin Lu and director G. Raymond Zage III – had submitted a preliminary proposal to take the company private at $18.00 per share in cashd18rn0p25nwr6d.cloudfront.netd18rn0p25nwr6d.cloudfront.net. By the end of the day, Grindr stock was hovering around $15.90 (up ~25.6%) on heavy volumebarchart.com, as
24 October 2025
·
Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Stock Performance: Clover Health stock has been exceptionally volatile in mid‑October 2025. On Oct. 21 it jumped ~8.7% intraday to ~$3.20 Marketbeat (from $2.92 prior close), and on Oct. 24 it spiked another ~18%, trading near $3.79 (from $3.20 close on Oct. 23) Reuters. According to Reuters data, that surge propelled CLOV close to its 52-week high (~$4.87) and far above its recent 50‑day moving average (around $2.82) Marketbeat. The 200-day average (~$3.02) was also eclipsed, signaling strong upward momentum Marketbeat. This rally has come on unusually heavy volume (15+ million shares traded on Oct. 24 vs. a 3‑month average
24 October 2025
·
Western Union Stock Edges Up on Q3 Beat – CEO Calls Crypto an “Opportunity”

Western Union Stock Edges Up on Q3 Beat – CEO Calls Crypto an “Opportunity”

Investors will be watching WU’s short-term outlook as it delivers Q4 results and commentary. Wolfe notes management’s plan to stabilize its core retail business, re-accelerate digital growth, and diversify into new financial servicesinvesting.com. In the near term, stock momentum may hinge on whether retail volumes recover after a 2024 slump, and whether earnings forecasts hold up under higher interest costs. In the long term, Western Union’s global brand, broad agent network and high dividend yield could appeal to conservative investors if the company succeeds in its turnaround. “Our goal is to provide more and better solutions…to give our customers a
24 October 2025
·
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intradayts2.tech, an increase of about 92%. This surge coincided with reports that VCN-01 had met the primary endpoints in the VIRAGE Phase 2b trial (see below). The very next trading day, Theriva disclosed a $4.0 million warrant inducement financing. Investors exercising warrants at $0.54 per share provided immediate cashts2.tech, but the announcement also trimmed the earlier stock rally – TOVX settled in the mid-$0.40 range by Oct. 16ts2.techts2.tech. In the days since, the stock has
24 October 2025
·
The $350B Shake-Up: How AI Summaries Rewire Publisher Traffic

Alphabet Stock Skyrockets to Record High, Nears $3 Trillion on AI Boom & Earnings Hype

Key Facts – October 24, 2025 Alphabet Rallies to Near Record Highs on AI Momentum Google’s headquarters campus in Mountain View. Alphabet’s stock (GOOG) has been on a tear, reaching all-time highs as investors cheer the company’s AI strides and strong financial performance. Alphabet’s stock is soaring into uncharted territory as of late October 2025. Shares of the Google parent company traded around $260–261 on Friday, flirting with the highest levels in its historystocktwits.com. Earlier this week, Alphabet hit an intraday peak just above $257 – marking a new record – and its latest surge has propelled the company’s market
24 October 2025
··
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Key Facts: – Neuphoria (Nasdaq: NEUP) shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial Investing. The AFFIRM-1 trial missed both primary and secondary endpoints, and the company immediately halted its social anxiety program and launched a full strategic review Investing Globenewswire. – CEO Spyros Papapetropoulos vowed to “conserve our cash position” while exploring options to “maximize value for shareholders” Globenewswire. Neuphoria will evaluate BNC210 in PTSD (where earlier data were promising) and otherwise cut spending. – NEUP stock fell from about $15.40 on Oct 20 to roughly $5
24 October 2025
Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?

Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?

Stock Price & Recent Movement Picard Medical stock has been extremely volatile this month. After its Aug. 29 IPO at $4.00, PMI traded mostly under $10, but shot higher in mid-October. On Oct. 20 the stock closed around $11.60, then hit a new 52-week peak near $13.68 by Oct. 23stockanalysis.com. However, on Oct. 24 trading opened sharply lower. By mid-day Oct. 24 the shares were about $3.30, erasing nearly all the prior week’s gainsinvesting.com. Investing.com confirms that as of Oct. 24, 2025 PMI was trading at $3.27 with a previous close of $13.20investing.com. This represents a collapse of roughly 75%
24 October 2025
·
General Dynamics Stock Rockets to Record High on Blowout Q3 Results and Defense Windfall

General Dynamics Stock Rockets to Record High on Blowout Q3 Results and Defense Windfall

Blowout Q3 Results and Rising Orders General Dynamics (NYSE: GD) stunned investors on Oct. 24, 2025, with a blowout third-quarter report. The defense and aerospace giant said Q3 revenue was $12.91 billion – about 10.6% higher than a year ago – beating the ~$12.57 billion analysts expectedbenzinga.com. GAAP earnings per share came in at $3.88, well above the $3.69 consensus estimatebenzinga.combenzinga.com. Operating income was $1.3 billion, and margins expanded by 20 basis points to 10.3%. Management highlighted exceptionally strong demand. “Each of our four segments grew earnings and backlog in the quarter, reflecting solid execution coupled with growing demand,” CEO Phebe Novakovic saidbenzinga.com.
24 October 2025
··
NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

Recent FDA Approval and Market Reaction NeurAxis’s Oct. 24, 2025 announcement of FDA 510(k) clearance for its PENFS device immediately grabbed market attention. The clearance authorizes use in adults (8 years and up) for functional abdominal pain associated with FD and nausea, a segment previously lacking any approved device treatmentinvesting.com. Investing.com and other outlets confirm this milestone — noting it’s “the first FDA clearance or approval” for an adult FD treatmentinvesting.com. In pre-market trading on Oct. 24, NRXS shares jumped (around +4% in early quotes) on the news, reflecting relief that FDA evidence support (from pediatric studies) could be extended
24 October 2025
·
Rocket Companies Stock Blasts Off After $14B Mega-Merger – Will RKT Keep Soaring?

Rocket Companies Stock Blasts Off After $14B Mega-Merger – Will RKT Keep Soaring?

Stock Price Rallies Amid Mortgage Market Shifts Rocket Companies’ stock has been on a wild ride this year. As of Oct. 24, RKT was trading around $16.94-$17 per sharegoogle.com – roughly flat on the day after some early swings (intraday high ~$17.10, low ~$16.41)google.com. That price is about 70-80% higher than where it started 2025, making Rocket a standout gainer in an otherwise sluggish housing sectoryoutube.com. The stock reached as high as the low-$20s in early October, when excitement over Rocket’s latest acquisition peaked, before cooling off. In fact, RKT shares have climbed about 54% since late March (when its
24 October 2025
·
American Airlines Lifts Profit Outlook, AAL Stock Rockets – Travel Boom or Turbulence Ahead?

American Airlines Lifts Profit Outlook, AAL Stock Rockets – Travel Boom or Turbulence Ahead?

Financial Results and Upgraded Outlook American Airlines reported mixed but encouraging third-quarter 2025 results, turning in record revenue but a small net loss. Total operating revenue reached $13.69 billion, a quarterly record that was flat versus a year ago but slightly above analyst expectations of ~$13.63 billionstockstory.org. The company posted a net loss of $114 million (roughly -$0.17 per share), which was narrower than feared – analysts had predicted a deeper $0.28 per-share lossstockstory.org. This smaller-than-expected lossreuters.com reflects improved cost management and resilient demand in lucrative segments. In fact, American noted that September turned the corner to positive unit revenue growth, as it
24 October 2025
·
1 … 342 343 344 345 346 … 586

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop